tbuckley/cabot-search huggingface dataset:
Intense Accumulation of Tl-201 In Carcinold Tumor of the Thymus
Authors: N Tonami, K Yokoyama, A Nonomura, J Taki, I Ishii, K Hisada, Y Watanabe, T Takashima
Journal: Clinical Nuclear Medicine (1994)

A case of carcinoid tumor of the thymus is presented in which Tl-201 SPECT demonstrated intense accumulation in the lesion. Conventional chest radiograph and CT scan in a 66-year-old man who had been experiencing cough and pain at the anterior part of the chest revealed a tumor in the anterior mediastinum, suggesting a thymoma. The tumor was clearly delineated in both early and delayed SPECT studies. On the delayed scan, the tumor was more prominently visualized with an extremely high uptake ratio of the lesion compared to the contralateral background; therefore, the tumor was believed to possess very prolonged Tl-201 retention. The pathological and immunohistochemical examinations confirmed that the area of intense Tl-201 uptake was rich in viable cells.
Efficacy of amoxapine in psychotic depression
Authors: R F Anton, J D Sexauer
Journal: American Journal of Psychiatry (1983)

Psychotic depression is a distinct clinical entity in that its response to tricyclic antidepressants is poor but its response to tricyclic antidepressant-antipsychotics is better. The authors report the favorable outcome of four patients with psychotic depression treated with amoxapine, a derivative of the antipsychotic loxapine. The elevation of serum prolactin during treatment in three patients suggests that postsynaptic dopamine blockade occurs with amoxapine treatment. This might account for the efficacy of amoxapine in psychotic depression.
Les hommes ayant des relations sexuelles avec d'autres hommes et la prévention du VIH/Sida en Suisse : 1987-2000
Authors: F Dubois-Arber, F Moreau-Gruet
Journal: Eurosurveillance (2002)

Bien que la derniere etude sur les comportements de prevention des hommes ayant des relations sexuelles avec d’autres hommes (HSH) revele une diminution des cas de Sida depuis 1992, on note une diminution du niveau de protection. Il en resulte que les declarations des cas de VIH pourraient etre plus nombreuses en 2001 qu’en 2000.
Syndromic inherited poikiloderma due to a <i>de novo</i> mutation in <i> <scp>FAM</scp> 111B </i>
Authors: T. Takeichi, A. Nanda, H.‐S. Yang, C.‐K. Hsu, J.Y.‐Y. Lee, H. Al‐Ajmi, M. Akiyama, M.A. Simpson, J.A. McGrath
Journal: British Journal of Dermatology (2016)
18F-FDG PET in Liver Transplantation Setting of Hepatocellular Carcinoma
Authors: Matthieu Bailly, Yann Venel, Isabelle Orain, Ephrem Salamé, Maria-Joao Ribeiro
Journal: Clinical Nuclear Medicine (2015)

Purpose The aim of this study was to evaluate the prognostic value of 18F-FDG PET/CT by predicting histopathological findings in the pretransplant evaluation of patients with hepatocellular carcinoma (HCC). Patients and Methods 18F-FDG PET/CT findings of 34 patients with HCC who underwent liver transplantation were reviewed retrospectively. Visual and quantitative analysis (tumor standardized uptake values normalized to the background activity of the liver: SUVmax T/L) was done. PET tumor characteristics were compared with the histological analysis (differentiation and microvascular invasion). All patients were followed up (mean, 12 months). Results Ten patients showed tumoral uptake greater than background activity (PET+). Higher-grade tumor was more common in the 18F-FDG–avid tumor group (P < 0.05). PET+ also showed more microvascular invasion at explant pathology (P < 0.05). Only 1 patient PET+ developed HCC early recurrence (4 months) with an SUVmax T/L of 1.64. Conclusions 18F-FDG uptake is predictive for microvascular invasion and tumor differentiation. This examination has a prognostic value regarding tumor recurrence after liver transplantation for HCC.
Obama presses Congress to agree to Zika funding
Authors: Michael McCarthy
Journal: BMJ (2016)

After meeting with health officials on 1 July, US President Barack Obama has called on Congress to back a bill to fund the US response to the Zika virus disease outbreak before it breaks for its seven week summer recess.

“We have to get the money from Congress over the next two weeks to make sure that we can begin to develop the effective vaccines, the mosquito abatement tools, the state emergency response dollars so that all of us are safe and we’re not …
Reply
Authors: Stefano Romeo, Paola Dongiovanni, Salvatore Petta, Jussi Pihalajamaki, Luca Valenti
Journal: Hepatology (2014)

Potential conflict of interest: Nothing to report. Author names in bold designate shared co‐first authorship. We showed that the TM6SF2 E167K and, possibly, PNPLA3 I148M variants, the major genetic risk factors predisposing to nonalcoholic fatty liver disease (NAFLD) and steatohepatitis, are associated with vascular damage in at‐risk subjects.1 Given that NAFLD has also been linked to increased risk of chronic kidney disease (CKD), Musso et al. evaluated whether these genetic variants influence kidney function and damage by examining estimated glomerular filtration rate (eGFR) and microalbuminuria in a cross‐sectional study comprising 202 subjects without obesity and diabetes. Consistently, with protection from atherosclerosis caused by decreased circulating levels of atherogenic lipoproteins,1 individuals carrying the 167K TM6SF2 allele had a lower risk of renal damage. Furthermore, the 148M PNPLA3 allele determining hepatocellular fat retention4 was independently associated with reduced eGFR and higher prevalence of albuminuria and CKD. These data are in line with our previous findings indicating that the 148M PNPLA3 risk variant is associated with accelerated atherogenesis in younger patients with NAFLD. Interestingly, PNPLA3 is also expressed in sinusoidal pericytes, that is, hepatic stellate cells, that store retinol and regulate its release in response to metabolic cues, whereas the 148M allele is a loss of function.5 It is currently unknown whether PNPLA3 is also involved in regulating the biological behavior of kidney pericytes, namely, glomerular podocytes, which play a major role in regulating glomerular filtration. It could be speculated that the 148M PNPLA3 risk allele favors unbalanced activation of pericytes, thereby leading to liver fibrosis on one hand and to kidney disease on the other. Therefore, we agree with Musso et al. that additional large, prospective studies are required to dissect the link between genetic risk factors for NAFLD as well as cardiovascular and renal disease. In addition, we propose further studies investigating the impact of the I148M PNPLA3 variant on the physiological activities of vascular pericytes, which are key players in the regulation of tissue fibrosis during aging in multiple organs.
Author response to the letter from Dr Hewett
Authors: Roald Bahr
Journal: British Journal of Sports Medicine (2016)

I appreciate the letter from Dr Hewett1 expressing his interest in my recent review paper,2 and am delighted to be able to address his concerns.

First, I confess to having used the term «predict» when quoting Dr Hewett's conclusions from his 2005 paper3 in two papers from our group. This was an overly optimistic error. But in all fairness it should be noted that the …
Growth characteristics of leukemic and normal hematopoietic cells in Ph' + chronic myelogenous leukemia and effects of intensive treatment
Authors: T Goto, M Nishikori, Z Arlin, T Gee, S Kempin, J Burchenal, A Strife, D Wisniewski, C Lambek, C Little, S Jhanwar, R Chaganti, B Clarkson
Journal: Blood (1982)
Topical herbal medicines for atopic eczema: a systematic review of randomized controlled trials
Authors: Y. Thandar, A. Gray, J. Botha, A. Mosam
Journal: British Journal of Dermatology (2016)

Despite the availability of medicines with proven efficacy, many patients use complementary or alternative medicines (CAMs) to manage atopic eczema (AE). Due to the lack of objective information on topical CAMs, this systematic review evaluates the current evidence for the efficacy and safety of topical herbal preparations in AE. Using Cochrane systematic review methodology, PubMed, the Cochrane Library, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL (via EBSCO), MEDLINE (via EBSCO), Proquest Health and Medical Complete, GREAT and CAM‐QUEST were searched from inception until June 2014. Bibliographies of retrieved studies were hand searched for further relevant trials. All controlled clinical trials of topical herbal medicines for AE in humans of any age were included regardless of the control intervention or randomization. Only English‐language publications were considered. Eight studies met the inclusion criteria. Seven investigated extracts of single plants and one an extract from multiple plants. Only two studies that showed a positive effect were considered to have a low risk of bias across all domains (those of liquorice gel and Hypericum perforatum). In these two, the test product was reported to be superior to placebo. Despite variations in diagnostic criteria and lack of validated tools for outcome assessments in one of these, the promising results may warrant continued research in better‐designed studies. No meta‐analysis was performed due to heterogeneity in all studies. There is currently insufficient evidence of efficacy for any topical herbal extract in AE. Many studies had methodological flaws and even those showing efficacy were single trials with small patient cohorts.
HIV Prevention 2020: a framework for delivery and a call for action
Authors: Karl L Dehne, Gina Dallabetta, David Wilson, Geoff P Garnett, Marie Laga, Elizabeth Benomar, Ade Fakoya, Rachel C Baggaley, Lisa J Nelson, Susan Kasedde, Alvaro Bermejo, Mitchell Warren, Clemens Benedikt
Journal: The Lancet HIV (2016)
Detection of Usutu virus infection in a healthy blood donor from south-west Germany, 2012
Authors: L Allering, H Jöst, P Emmerich, S Günther, E Lattwein, M Schmidt, E Seifried, V Sambri, K Hourfar, J Schmidt-Chanasit
Journal: Eurosurveillance (2012)

From September 2011 until November 2012, 31 serum samples from German patients with clinically suspected acute Usutu virus (USUV) infections were tested for USUV-specific antibodies. All samples tested negative. In addition, 4,200 serum samples from healthy blood donors from south-west Germany were collected in January 2012 and also analysed for the presence of specific antibodies. One sample tested positive for USUV-IgG and -IgM. Thus, the seroprevalence of USUV antibodies in healthy blood donors from south-west Germany was low in January 2012.
COMMENTS
Authors: R. H. F.
Journal: American Journal of Psychiatry (1963)

Back to table of contents Previous article Next article ArticleNo AccessCOMMENTSCOMMUNITY MENTAL HEALTH CENTERSR. H. F.R. H. F.Search for more papers by this authorPublished Online:1 Apr 2006https://doi.org/10.1176/ajp.120.5.506AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail "COMMENTS ." American Journal of Psychiatry, 120(5), pp. 506–507 Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Purchase Save for later Item saved, go to cart PPV Articles - American Journal of Psychiatry $35.00 Add to cart PPV Articles - American Journal of Psychiatry Checkout Please login/register if you wish to pair your device and check access availability. Not a subscriber? Subscribe Now / Learn More PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development. Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.). FiguresReferencesCited byDetailsCited ByNone Volume 120Issue 5 November 1963Pages 506-507 Metrics PDF download History Published online 1 April 2006 Published in print 1 November 1963
Functional Flow Patterns and Static Blood Pooling in Tumors Revealed by Combined Contrast-Enhanced Ultrasound and Photoacoustic Imaging
Authors: Avinoam Bar-Zion, Melissa Yin, Dan Adam, F. Stuart Foster
Journal: Cancer Research (2016)

Alterations in tumor perfusion and microenvironment have been shown to be associated with aggressive cancer phenotypes, raising the need for noninvasive methods of tracking these changes. Dynamic contrast-enhanced ultrasound (DCEUS) and photoacoustic (PA) imaging serve as promising candidates-one has the ability to measure tissue perfusion, whereas the other can be used to monitor tissue oxygenation and hemoglobin concentration. In this study, we investigated the relationship between the different functional parameters measured with DCEUS and PA imaging, using two morphologically different hind-limb tumor models and drug-induced alterations in an orthotopic breast tumor model. Imaging results showed some correlation between perfusion and oxygen saturation maps and the ability to sensitively monitor antivascular treatment. In addition, DCEUS measurements revealed different vascular densities in the core of specific tumors compared with their rims. Noncorrelated perfusion and hemoglobin concentration measurements facilitated discrimination between blood lakes and necrotic areas. Taken together, our results illustrate the utility of a combined contrast-enhanced ultrasound method with photoacoustic imaging to visualize blood flow patterns in tumors. Cancer Res; 76(15); 4320-31. ©2016 AACR.
Erlotinib (E) combined with cisplatin (C) and radiotherapy (RT) for patients with locally advanced squamous cell cervical cancer: A phase II trial
Authors: C. G. Ferreira, F. Erlich, C. C. Carmo, C. Viegas, I. J. Cidade, C. C. Camisao, I. Á. Small, K. Fontao, R. G. Martins, A. N. Rodrigues MD
Journal: Journal of Clinical Oncology (2008)

5511 Background: New strategies beyond standard chemoradiation (CRT) are needed in locally advanced squamous cell cervical carcinoma. Combinations that increase the complete response rates (CR) may lead to longer progression-free and overall survival in cervical cancer. Pre-clinical data indicates that inhibition of epidermal growth factor receptor (EGFR) enhances the effect of C and RT. We previously reported the results of the phase I of E when administered concurrently with standard CRT for locally advanced cervical cancer that defined the safety and the maximal tolerated dose of 150mg/day for the combination. Methods: Eligibility criteria included histologically proven squamous cell cervical carcinoma, stage IIB to IIIB; no prior therapy; ECOG PS<3 and adequate end-organ functions. Patients (pts) received E 150mg/day one week before and combined with C (40mg/m2, weekly, 5 cycles) and RT (external beam RT - 4500cGy in 25 fractions, followed by 4 fractions/600cGy/weekly of brachytherapy). Results: Between 02/2006 and 10/2007, 37 pts were enrolled. Two pts did not complete the planned schedule (one presented Raynaud’s Syndrome and had C interrupted and one presented grade 4 hepatotoxicity). Twelve pts are still under treatment, 25 pts are available for toxicity and 23 for response evaluation. Within the 23 pts who received through E+CRT, median duration of treatment was 77(64–106) days. Pts presented median age 43(28–68), stage IIB 11(47.8%), IIIA 1(4.3%) and IIIB 11(47.8%). Overall E+CRT was well tolerated. Significant grade 3 toxicities were diarrhea and skin rash in 3(12%) and 5 (20%) pts, respectively. Twenty-one pts (91.3%; IC 95% 70.5 - 98.5) presented CR and 2 (8.7%) presented partial response. With a median follow-up of 9(3–25) months, none of the 23 pts progressed. Conclusions: Our data indicate that the combination of E+CRT is feasible and leads to high CR (91.3%) compared to historical CRT data (38–75%). To our knowledge this is the first report of E+CRT in cervical cancer pts. The trial has finished accrual and final results will be presented at the meeting. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Roche
Frequency, intensity, and correlates of financial distress (FD) among advanced cancer patients (AdCa).
Authors: Marvin Omar Delgado-Guay, Jeanette Ferrer, Alyssa G. Rieber, Wadih Rhondali, Jewel Ochoa, Hilda Cantu, Gary B. Chisholm, Janet L. Williams, Susan Frisbee-Hume, Eduardo Bruera
Journal: Journal of Clinical Oncology (2014)

9635 Background: Financial problems are frequent and severe for AdCa. There is limited data on the effects of FD on suffering and quality of life(QOL) of AdCa. In this prospective cross sectional study, we examined the frequency of FD and its correlates in AdCa. Methods: We interviewed 149 AdCa, 77 at a Comprehensive Cancer Center(CCC) and 72 at a General Public Hospital(GPH). AdCa completed self-rated FD(subjective experience of distress attributed to financial problems) numeric rating scale(0=best, 10=worst) and also validated questionnaires assessing symptoms(ESAS), psychosocial distress(HADS), and QOL(FACT-G). Results: Median age (Interquartile range:IQR): 60 years(55-65). 74/149(50%) were female. 78/149(52%) were married. 48/77 (62%) at CCC vs. 13/72(18%) at GPH were white (p<0.0001); 21/77(27%) vs. 32/72(38%) were African American(p<0.0001), and 7/77(9%) vs. 27/72(38%) were Hispanics(p<0.0001). 44/77(58%) at CCC vs. 14/72(19%) at GPH had college education and an advanced degree(p<0.0001). The median(IQR) current income was $3,000($1,400-$7,000) for CCC vs. $940($350-$1,300) at GPH, p=0.0017. 72(51%) AdCa self-reported as middle class before cancer diagnosis vs. 52(39%) at the time of the evaluation(p<0.0001). FD was present in 65/75[86% (95%CI=76-93%)] at CCC vs. 65/72[90% (81-96%)] p=0.45. However the median intensity of FD(IQR) at CCC was 4(1-7) vs. 8(3-10), p=0.0003. AdCa reported that FD was affecting their general well-being(0=not at all, 10=very much) with a median(IQR) of 5(1-8). FD was reported as more severe than physical distress, distress about physical functioning, social/family distress and emotional distress by 45(31%), 46(32%), 64(43%), and 55(37%) AdCa respectively (all significantly worse for GPH). Spearman Correlation of FD with financial burden r=0.53, p<0.0001; FACT-G r=-0.23, p=0.005; HADS-Anxiety r=0.27, p=0.001; ESAS-Anxiety r=0.2, p=0.01; and ESAS-depression r=0.18 p=0.03. Conclusions: FD was very frequent in both groups but intensity was double among GPH patients. FD was associated with worse anxiety, depression and poor QOL. More research is warranted to confirm these associations and establish interventions to improve this aspect of the care of AdCa.
P-201 A Comparative Study for Effectiveness of Irreversible Electroporation Ablation according to Therapeutic Method: Colon Cancer Animal Model
Authors: H.S. Choi, H.J. Chun, J.M. Lee, I.K. Yoo, J.M. Lee, S.H. Kim, E.S. Kim, B. Keum, Y.T. Jeen, H.S. Lee, C.D. Kim
Journal: Annals of Oncology (2016)
Upper and Lower Respiratory Tract Infections By Respiratory Viruses in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Authors: Erden Atilla, Pinar Ataca, Didem Sahin, Pervin Topcuoglu, Istar Dolapci, Alper Tekeli, Selami Kocak Toprak, Sinem Civriz Bozdag, Meltem Kurt Yuksel, Muhit Ozcan, Gunhan Gurman
Journal: Blood (2015)
Vitamin D: Metabolism and Function.
Authors: H F DeLuca
Journal: Annals of Internal Medicine (1980)

From intensive work carried out during the past decade, it is clear that vitamin D must be metabolized before it can function.1 One of the central metabolites in this phenomenon is 25-hydroxyvitamin D, (25OHD3), to which this publication is devoted. It is also known that 25OHD3 is metabolized further to an active hormone, 1,25-dihydroxyvitamin D3 (1,25[OH]2D3). This report will review the physiology and biochemistry underlying the use of calcifediol (25OHD3) in the treatment of disease even in circumstances where there is a lack of 1,25(OH)2D3.
Essential Role of the PfRh5/PfRipr/CyRPA Complex during Plasmodium falciparum Invasion of Erythrocytes
Authors: Jennifer C. Volz, Alan Yap, Xavier Sisquella, Jenn K. Thompson, Nicholas T.Y. Lim, Lachlan W. Whitehead, Lin Chen, Marko Lampe, Wai-Hong Tham, Danny Wilson, Thomas Nebl, Danushka Marapana, Tony Triglia, Wilson Wong, Kelly L. Rogers, Alan F. Cowman
Journal: Cell Host & Microbe (2016)
P-275 First-line pembrolizumab versus investigator-choice chemotherapy for mismatch repair–deficient or microsatellite instability–high metastatic colorectal carcinoma: randomized, phase 3 KEYNOTE-177 study
Authors: Diaz Luis, Le Dung, Yoshino Takayuki, André Thierry, Bendell Johanna, Koshiji Minori, Zhang Yinghua, Kang S. Peter, Lam Bao, Jäger Dirk
Journal: Annals of Oncology (2016)
The impact of CALGB 9344 on adjuvant taxane (T) Use for breast cancer (BC)
Authors: S. H. Giordano, Z. Duan, Y.-F. Kuo, G. N. Hortobagyi, J. Freeman, J. S. Goodwin
Journal: Journal of Clinical Oncology (2005)

669 Background: In 5/98 the results of CALGB 9344 were presented at ASCO: adjuvant paclitaxel provided a significant survival benefit for women with lymph node (LN) positive BC. We have now evaluated the impact of this oral presentation on the use of adjuvant T in older women. Methods: Women who had Stage I-III BC diagnosed 1994–1999, age ≥ 65, and were treated with definitive surgery were identified through the SEER-Medicare database. Adjuvant chemotherapy (C) use was identified through J code claims within a year of diagnosis. Multivariate logistic regression analysis was used to determine the independent effects of date of treatment (4/94–5/98, 6/98–12/99), age, race, lymph node status, tumor size, grade, and estrogen receptor status on use of adjuvant T. Results: 27,408 women met eligibility criteria, of whom 3538 (12.9%) received adjuvant C. Median age was 71.5 yrs. Among all patients treated with C, 12.2% received adjuvant T. A plot of month-by-month use of T showed no clear increase over 1994–1997. However, in 1998 a marked shift was seen with a steep increase in use of T. The use of T increased from 8.4% to 19.4% (p<0.001) from the 12 months before to after 5/98. Initially, this increase was confined to patients with LN positive disease (8.0% to 29.7% p<0.001). Over time, this effect spilled over to patients with LN negative disease. By the fourth quarter of 1999, 33.0% of adjuvant C patients received a T (40.7% of women with LN positive disease and 14.3% of women with LN negative disease). In multivariate analysis, patients treated post 5/98 had 14.5 times (95% CI: 10.2–20.7) the odds of being treated with T as a part of their C regimen. Other significant independent predictors of adjuvant T use included: patient age, number of LN involved, and tumor size. Conclusions: The oral presentation of a single study at a national conference had a dramatic effect on the use of adjuvant T among older women, prior to FDA approval (10/99) or study publication (3/03). No significant financial relationships to disclose.
Pulmonary Function Abnormalities 5 Years or More Following Myeloablative and Non-Myeloablative Allogeneic Stem Cell Transplantation for Hematological Disorders - Impact of Chronic GVHD.
Authors: Bipin N. Savani, Ramaprasad Srinivasan, Aldemar Montero, Anurag Singh, Aarthi Shenoy, Shervin Kamipour, Richard Childs, A. John Barrett
Journal: Blood (2005)